Royalty Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Royalty Pharma heeft een totaal eigen vermogen van $9.8B en een totale schuld van $7.6B, wat de schuld-eigenvermogensverhouding op 78% brengt. De totale activa en totale passiva bedragen respectievelijk $17.7B en $7.9B. De EBIT Royalty Pharma is $960.2M waardoor de rentedekking 7.1 is. Het heeft contanten en kortetermijnbeleggingen van $1.8B.
Belangrijke informatie
78.0%
Verhouding schuld/eigen vermogen
US$7.60b
Schuld
| Rente dekkingsratio | 7.1x |
| Contant | US$1.80b |
| Aandelen | US$9.75b |
| Totaal verplichtingen | US$7.90b |
| Totaal activa | US$17.66b |
Recente financiële gezondheidsupdates
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Recent updates
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth
Aug 18Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $2.6B ) RPRX } overtreffen de korte termijn passiva ( $275.7M ).
Langlopende schulden: De kortetermijnactiva van RPRX ( $2.6B ) dekken de langetermijnschulden ( $7.6B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 59.5% ) RPRX wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van RPRX is de afgelopen 5 jaar gedaald van 119.7% naar 78%.
Schuldendekking: De schuld van RPRX wordt goed gedekt door de operationele kasstroom ( 35.1% ).
Rentedekking: De rentebetalingen op de schuld van RPRX worden goed gedekt door EBIT ( 7.1 x dekking).